Sanofi to buy US biopharma group Blueprint for over $9 billion
PARIS: France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest healthcare deal in Europe this year, according to LSEG data.
Blueprint is a specialist in treatments for systemic mastocytosis, a rare immunological disorder.
The acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson.
The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline.
Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said.
Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, which is characterised by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs.
Sanofi to invest at least $20 billion in the US through 2030
The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology.
It is the latest in a series of deals struck by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx.
Sanofi's shares opened little changed.
Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, would be approximately $9.5 billion on a fully diluted basis.
Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further acquisitions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
2 days ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Business Recorder
2 days ago
- Business Recorder
Sanofi to buy US biopharma group Blueprint for over $9 billion
PARIS: France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest healthcare deal in Europe this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare immunological disorder. The acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson. The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, which is characterised by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. Sanofi to invest at least $20 billion in the US through 2030 The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. It is the latest in a series of deals struck by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx. Sanofi's shares opened little changed. Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, would be approximately $9.5 billion on a fully diluted basis. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further acquisitions.
Business Recorder
14-05-2025
- Business Recorder
Sanofi to invest at least $20 billion in the US through 2030
French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which includes an increase in research and development spending and the allocation of billions of dollars to US manufacturing. The announcement makes Sanofi the latest drugmaker to announce large-scale U.S. investments in response to Trump's push to onshore pharmaceutical manufacturing.
